Kumar Srinivasan

Kumar Srinivasan is the President and Chief Executive Officer of Wugen, Inc., a clinical-stage biotechnology company focused on developing allogeneic cell therapies for various malignancies. He assumed this role on March 13, 2023, succeeding Dan Kemp.16

Background and Experience

• Education: Dr. Srinivasan holds a Ph.D. in Chemistry from Case Western Reserve University and an MBA with a concentration in Finance and Strategy from the University of Chicago's Booth School of Business. He also completed postdoctoral research at Caltech.24

• Professional Experience:

  • Prior to joining Wugen, he served as the Executive Vice President and Chief Business Officer at Turning Point Therapeutics, where he was instrumental in the company's sale to Bristol Myers Squibb for $4.1 billion.23
  • He has over 25 years of experience in the pharmaceutical and biotechnology sectors, including significant roles at AstraZeneca, where he was the Vice President and Global Head of Business Development for the BioPharmaceutical business unit. His tenure there included leading licensing agreements for COVID-19 vaccines and monoclonal antibody cocktails during the pandemic.24
  • Earlier in his career, he held senior positions at Wyeth, Vivoryon (formerly Probiodrug), and Torrey Pines Therapeutics.35

Leadership Role at Wugen

As CEO, Dr. Srinivasan is expected to leverage his extensive expertise in corporate strategy, business development, and alliance management to advance Wugen’s mission in oncology.12 His leadership is anticipated to drive growth and innovation within the company as it develops therapies aimed at treating hematological and solid tumor malignancies.16